EC 4 Good Investments For Good Friday

Edwards Lifesciences Corp (EW)

This Irvine, CA-based company is a leading player in the field of heart valve therapy. With an increase in aging population, the number of people with cardiovascular disease is likely to grow manifold. Edwards Lifesciences is currently well placed and should be poised even better in the future to serve this market with its leading minimally invasive technologies.

Zacks Rank #2 (Buy)
P/E: 33.97
Long-term EPS growth: 15.1%
Estimate Revision (F1): 4.5%

Luminex Corp. (LMNX - Snapshot Report)

This Austin, TX-based company’s open-architecture multiplexing xMAP (Multi-Analyte Profiling) technology is sold worldwide. 2015 will be a key transitional year for Luminex as it prepares for the launch of ARIES as well as its new multiplexing Assay NxTAG RPP (Respiratory Pathogen Panel). While ARIES is positioned to target the low-plex testing market, NxTAG RPP eyes the moderate to high volume labs in the multiplex market.

Zacks Rank #2 (Buy)
P/E: 31.62
Long-term EPS growth: 18.8%
Estimate Revision (F1): 4.1%

RTI Surgical (RTIX - Snapshot Report)

This Alachua, FL-based company offers orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. The company’s expanding product portfolio that comprises sports medicine, spine, orthofixation, and BGS & general orthopedic market is a key growth driver.

Zacks Rank: #2 (Buy)
P/E: 25.12
Long-term EPS growth: 15%
Estimate Revision (F1): 17.6%


Despite reimbursement-related concerns, 2015 is forecasted to be a transition year for the medical devices sector. Healthcare providers are expected to spend more on the backdrop of an improving U.S. economy, which will eventually drive top-line growth. Additionally, the ongoing legislation to repeal a much debated 2.3% federal excise tax under Obamacare is good news for these companies, as it will boost earnings significantly.

View single page >> |

By applying the Zacks Rank to mutual funds, investors can find funds that not only outpaced the market in the past but are also expected to outperform going forward. ...

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.